Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP‐1 and its action on numer...

Descripción completa

Detalles Bibliográficos
Autores principales: Helmstädter, Johanna, Keppeler, Karin, Küster, Leonie, Münzel, Thomas, Daiber, Andreas, Steven, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
GLP1 RECEPTOR LIGANDS (BJP 75th ANNIVERSARY) ‐ THEMED ISSUE REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820186/
https://www.ncbi.nlm.nih.gov/pubmed/33764504
http://dx.doi.org/10.1111/bph.15462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820186/
https://www.ncbi.nlm.nih.gov/pubmed/33764504
http://dx.doi.org/10.1111/bph.15462

Ejemplares similares